PHVS vs. GRFS, LVTX, MYNZ, NLSP, PROC, QLI, ATNFW, SXTPW, ACONW, and AIMDW
Should you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Grifols (GRFS), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Procaps Group (PROC), Qilian International Holding Group (QLI), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), and Ainos (AIMDW). These companies are all part of the "medical" sector.
Grifols (NASDAQ:GRFS) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends.
Grifols has a net margin of 0.90% compared to Grifols' net margin of 0.00%. Pharvaris' return on equity of 1.73% beat Grifols' return on equity.
Grifols has higher revenue and earnings than Pharvaris.
Grifols has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -3.02, suggesting that its stock price is 402% less volatile than the S&P 500.
Grifols presently has a consensus target price of $10.50, suggesting a potential upside of 36.36%. Pharvaris has a consensus target price of $31.50, suggesting a potential upside of 54.79%. Given Grifols' stronger consensus rating and higher possible upside, analysts plainly believe Pharvaris is more favorable than Grifols.
Grifols received 315 more outperform votes than Pharvaris when rated by MarketBeat users. However, 64.71% of users gave Pharvaris an outperform vote while only 55.95% of users gave Grifols an outperform vote.
In the previous week, Pharvaris had 5 more articles in the media than Grifols. MarketBeat recorded 10 mentions for Pharvaris and 5 mentions for Grifols. Pharvaris' average media sentiment score of 0.04 beat Grifols' score of -0.60 indicating that Grifols is being referred to more favorably in the media.
Summary
Grifols beats Pharvaris on 8 of the 13 factors compared between the two stocks.
Get Pharvaris News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharvaris Competitors List
Related Companies and Tools
